Regencell Bioscience Holdings Stock Current Liabilities
| RGC Stock | USD 5.35 0.25 4.90% |
Regencell Bioscience Holdings fundamentals help investors to digest information that contributes to Regencell Bioscience's financial success or failures. It also enables traders to predict the movement of Regencell Stock. The fundamental analysis module provides a way to measure Regencell Bioscience's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Regencell Bioscience stock.
As of April 27, 2024, Total Current Liabilities is expected to decline to about 518.9 K. In addition to that, Non Current Liabilities Total is expected to decline to about 27.8 K. Regencell | Current Liabilities |
Regencell Bioscience Holdings Company Current Liabilities Analysis
Regencell Bioscience's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current Regencell Bioscience Current Liabilities | 551.3 M |
Most of Regencell Bioscience's fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Regencell Bioscience Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Regencell Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for Regencell Bioscience is extremely important. It helps to project a fair market value of Regencell Stock properly, considering its historical fundamentals such as Current Liabilities. Since Regencell Bioscience's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Regencell Bioscience's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Regencell Bioscience's interrelated accounts and indicators.
Click cells to compare fundamentals
Regencell Current Liabilities Historical Pattern
Today, most investors in Regencell Bioscience Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Regencell Bioscience's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Regencell Bioscience current liabilities as a starting point in their analysis.
Regencell Bioscience Current Liabilities |
| Timeline |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
Regencell Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, Regencell Bioscience Holdings has a Current Liabilities of 551.3 M. This is 68.54% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The current liabilities for all United States stocks is 93.02% higher than that of the company.
Regencell Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Regencell Bioscience's direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Regencell Bioscience could also be used in its relative valuation, which is a method of valuing Regencell Bioscience by comparing valuation metrics of similar companies.Regencell Bioscience is currently under evaluation in current liabilities category among related companies.
Regencell Fundamentals
| Return On Equity | -0.42 | ||||
| Return On Asset | -0.26 | ||||
| Current Valuation | 58.48 M | ||||
| Shares Outstanding | 13.01 M | ||||
| Shares Owned By Insiders | 88.76 % | ||||
| Shares Owned By Institutions | 0.12 % | ||||
| Number Of Shares Shorted | 9.88 K | ||||
| Price To Earning | 26.21 X | ||||
| Price To Book | 4.12 X | ||||
| EBITDA | (5.5 M) | ||||
| Net Income | (6.06 M) | ||||
| Cash And Equivalents | 59.41 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 463.67 K | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 13.94 X | ||||
| Book Value Per Share | 0.92 X | ||||
| Cash Flow From Operations | (4.96 M) | ||||
| Short Ratio | 1.57 X | ||||
| Earnings Per Share | (0.45) X | ||||
| Price To Earnings To Growth | 2.15 X | ||||
| Number Of Employees | 12 | ||||
| Beta | -0.35 | ||||
| Market Capitalization | 69.62 M | ||||
| Total Asset | 12.62 M | ||||
| Retained Earnings | (17.32 M) | ||||
| Working Capital | 11.01 M | ||||
| Current Asset | 438.2 M | ||||
| Current Liabilities | 551.3 M | ||||
| Five Year Return | 4.37 % | ||||
| Net Asset | 12.62 M |
About Regencell Bioscience Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Regencell Bioscience Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Regencell Bioscience using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Regencell Bioscience Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Regencell Bioscience in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Regencell Bioscience's short interest history, or implied volatility extrapolated from Regencell Bioscience options trading.
Currently Active Assets on Macroaxis
When determining whether Regencell Bioscience offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regencell Bioscience's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regencell Bioscience Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regencell Bioscience Holdings Stock:Check out Regencell Bioscience Piotroski F Score and Regencell Bioscience Altman Z Score analysis. Note that the Regencell Bioscience information on this page should be used as a complementary analysis to other Regencell Bioscience's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Complementary Tools for Regencell Stock analysis
When running Regencell Bioscience's price analysis, check to measure Regencell Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regencell Bioscience is operating at the current time. Most of Regencell Bioscience's value examination focuses on studying past and present price action to predict the probability of Regencell Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regencell Bioscience's price. Additionally, you may evaluate how the addition of Regencell Bioscience to your portfolios can decrease your overall portfolio volatility.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Stocks Directory Find actively traded stocks across global markets | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |
Is Regencell Bioscience's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regencell Bioscience. If investors know Regencell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regencell Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.45) | Return On Assets (0.26) | Return On Equity (0.42) |
The market value of Regencell Bioscience is measured differently than its book value, which is the value of Regencell that is recorded on the company's balance sheet. Investors also form their own opinion of Regencell Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Regencell Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regencell Bioscience's market value can be influenced by many factors that don't directly affect Regencell Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regencell Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Regencell Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regencell Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.